ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES/ iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation. On February 10, 2014, it established a Kanagawa-based wholly owned subsidiary. On June 30, 2014, it acquired 85.2% interests in Reinnervate Limited, a UK-based company. On July 1, 2014, it fully acquired Reinnervate Limited. In July, 2014, it acquired BioServe Biotechnologies, Ltd. On September 2, 2014, it completed the acquisition of BioServe Biotechnologies, Ltd.

Biotechnology

Health Care

Test & Measurement

REPROCELL

Chikafumi Yokoyama

Allison Francis

Litong Liu

Karen Bingham

Yasuyuki Asai

Chirag Tawde

Graeme Macluskie

Ejaz Ansari

David Bunton

Rama Modali

Yoshiyuki Yamakawa

Daisuke Usui

The Leadership Team at ReproCELL is responsible for driving the company's strategic vision and overall direction in the field of stem cell technologies. This team focuses on overseeing business operations, fostering innovation in regenerative medicine, and ensuring successful integration of acquired businesses while nurturing global expansion in Europe and the USA. Their collective expertise guides collaboration across segments to enhance research and clinical applications of stem cell therapies.

Leadership Team

Research and Development

Sales and Marketing

Leadership Team

About

Team members

Other teams at REPROCELL

Research and Development

Sales and Marketing